EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieKohortenstudie

The Mitochondrial-Derived Peptide MOTS-c May Refine Mortality and Cardiovascular Risk Prediction in Chronic Hemodialysis Patients: A Multicenter Cohort Study

Davide Bolignano, Marta Greco, Pierangela Presta, Anila Duni, Mariateresa Zicarelli, Simone Mercuri, Efthymios Pappas, Lampros Lakkas, Michela Musolino, Katerina K Naka, Roberta Misiti, Daniela Patrizia Foti und 3 weitere

Blood Purification · 2024

DOI: 10.1159/000540303 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Blood Purification, 2024. Verfasst von Davide Bolignano und 14 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology and Dialysis Unit, Magna Graecia University, Catanzaro, Italy. Hauptthemen laut MEDLINE: Renal Dialysis, Cardiovascular Diseases, Biomarkers, Kidney Failure, Chronic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Uremic patients exhibit remarkably increased rates of mortality and cardiovascular (CV) events, but risk prediction in this setting remains difficult. Systemic mitochondrial dysfunction is pervasive in end-stage kidney disease and may contribute to CV complications. We tested the clinical significance of circulating MOTS-c, a small mitochondrial-derived peptide, as a biomarker for improving mortality and CV risk prediction in hemodialysis (HD) patients.

Methods

We conducted a prospective, observational, multicenter study on 94 prevalent HD patients. The study endpoint was a composite of all-cause mortality and non-fatal CV events. The diagnostic and prognostic capacities of predictive models based on cohort-related risk factors were tested before and after the inclusion of MOTS-c.

Results

MOTS-c levels were higher in HD patients than in controls (p < 0.001) and even more elevated (p = 0.01) in the 53 individuals experiencing the combined endpoint during follow-up (median duration: 26.5 months). MOTS-c was independently associated with the endpoint at either multivariate logistic (OR 1.020; 95% CI: 1.011–1.109; p = 0.03) or Cox regression analyses (HR 1.004; 95% CI: 1.000–1.025; p = 0.05) and the addition of this biomarker to prognostic models including the other cohort-related risk predictors (age, left ventricular mass, evidence of diastolic dysfunction, diabetes, pulse pressure) significantly improved the calibration, risk variability explanation, discrimination (receiver operating characteristic area under the curve from 0.727 to 0.743; C-index from 0.658 to 0.700), and particularly, the overall reclassification capacity (NRI 15.87%; p = 0.01).

Conclusions

In HD patients, the mitochondrial-derived peptide MOTS-c may impart significant information to refine CV risk prediction, beyond cohort-related risk factors. Future investigations are needed to generalize these findings in larger and more heterogeneous cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal DialysisCardiovascular DiseasesBiomarkersKidney Failure, ChronicHumansMaleFemaleMiddle AgedAgedProspective StudiesRisk FactorsMitochondrial ProteinsPrognosisCohort Studies

Stichwörter der Autor:innen

Cardiovascular riskEnd-stage kidney diseaseHemodialysisMOTS-cMortality

Substanzen

BiomarkersMOTS-c peptide, humanMitochondrial Proteins

Autor:innen und Institutionen

  • Nephrology and Dialysis Unit, Magna Graecia University, Catanzaro, Italy.
  • Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy.
  • Department of Health Sciences, Magna Graecia University, Catanzaro, Italy.
  • Clinical Pathology Lab, Magna Graecia University, Catanzaro, Italy.
  • Department of Nephrology, School of Medicine, University of Ioannina, Ioannina, Greece.
  • Hemodialysis Unit, General Hospital of Filiates, Filiates, Greece.

Zitieren

APA

Bolignano, D., Greco, M., Presta, P., Duni, A., Zicarelli, M., Mercuri, S., Pappas, E., Lakkas, L., Musolino, M., Naka, K. K., Misiti, R., Foti, D. P., Andreucci, M., Coppolino, G., & Dounousi, E. (2024). The Mitochondrial-Derived Peptide MOTS-c May Refine Mortality and Cardiovascular Risk Prediction in Chronic Hemodialysis Patients: A Multicenter Cohort Study. Blood Purification. https://doi.org/10.1159/000540303

Vancouver

Bolignano D, Greco M, Presta P, Duni A, Zicarelli M, Mercuri S, et al. The Mitochondrial-Derived Peptide MOTS-c May Refine Mortality and Cardiovascular Risk Prediction in Chronic Hemodialysis Patients: A Multicenter Cohort Study. Blood Purification. 2024. doi:10.1159/000540303

BibTeX
@article{Bolignano2024,
  author = {Bolignano, Davide and Greco, Marta and Presta, Pierangela and Duni, Anila and Zicarelli, Mariateresa and Mercuri, Simone and Pappas, Efthymios and Lakkas, Lampros and Musolino, Michela and Naka, Katerina K and Misiti, Roberta and Foti, Daniela Patrizia and Andreucci, Michele and Coppolino, Giuseppe and Dounousi, Evangelia},
  title = {The Mitochondrial-Derived Peptide MOTS-c May Refine Mortality and Cardiovascular Risk Prediction in Chronic Hemodialysis Patients: A Multicenter Cohort Study},
  journal = {Blood Purification},
  year = {2024},
  doi = {10.1159/000540303}
}
Kostenlos starten →